Comparative Pharmacology
Head-to-head clinical analysis: ABSTRAL versus DARVOCET N 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSTRAL versus DARVOCET N 100.
ABSTRAL vs DARVOCET-N 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and providing analgesia.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Darvocet-N 100 contains propoxyphene napsylate 100 mg and acetaminophen 650 mg. For moderate to moderately severe pain, the typical adult dose is 1 tablet orally every 4 hours as needed. Maximum: 6 tablets per day (600 mg propoxyphene napsylate, 3900 mg acetaminophen).
None Documented
None Documented
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Propoxyphene: 6-12 hours (prolonged in elderly and hepatic impairment); norpropoxyphene metabolite: 30-36 hours. Acetaminophen: 1.5-3 hours.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Propoxyphene: primarily hepatic metabolism to norpropoxyphene, renal excretion of metabolites (20-25% unchanged propoxyphene). Acetaminophen: renal excretion of glucuronide and sulfate conjugates (90-95% total), 2-4% unchanged.
Category C
Category C
Opioid Analgesic
Opioid Analgesic